Src family kinases in tumor progression and metastasis - PubMed (original) (raw)
Review
Src family kinases in tumor progression and metastasis
Justin M Summy et al. Cancer Metastasis Rev. 2003 Dec.
Abstract
The Src family of non-receptor protein tyrosine kinases plays critical roles in a variety of cellular signal transduction pathways, regulating such diverse processes as cell division, motility, adhesion, angiogenesis, and survival. Constitutively activated variants of Src family kinases, including the viral oncoproteins v-Src and v-Yes, are capable of inducing malignant transformation of a variety of cell types. Src family kinases, most notably although not exclusively c-Src, are frequently overexpressed and/or aberrantly activated in a variety of epithelial and non-epithelial cancers. Activation is very common in colorectal and breast cancers, and somewhat less frequent in melanomas, ovarian cancer, gastric cancer, head and neck cancers, pancreatic cancer, lung cancer, brain cancers, and blood cancers. Further, the extent of increased Src family activity often correlates with malignant potential and patient survival. Activation of Src family kinases in human cancers may occur through a variety of mechanisms and is frequently a critical event in tumor progression. Exactly how Src family kinases contribute to individual tumors remains to be defined completely, however they appear to be important for multiple aspects of tumor progression, including proliferation, disruption of cell/cell contacts, migration, invasiveness, resistance to apoptosis, and angiogenesis. This review details the evidence for Src family activation in human tumors, and emphasizes possible consequences to tumor progression. Given the ability of Src and its family members to participate in so many aspects of tumor progression and metastasis, Src family kinases are attractive targets for future anti-cancer therapeutics.
Similar articles
- Targeting Src signaling in metastatic bone disease.
Araujo J, Logothetis C. Araujo J, et al. Int J Cancer. 2009 Jan 1;124(1):1-6. doi: 10.1002/ijc.23998. Int J Cancer. 2009. PMID: 18942061 Review. - Regulation of angiogenesis and vascular permeability by Src family kinases: opportunities for therapeutic treatment of solid tumors.
Park SI, Shah AN, Zhang J, Gallick GE. Park SI, et al. Expert Opin Ther Targets. 2007 Sep;11(9):1207-17. doi: 10.1517/14728222.11.9.1207. Expert Opin Ther Targets. 2007. PMID: 17845146 Review. - Src signaling in cancer invasion.
Guarino M. Guarino M. J Cell Physiol. 2010 Apr;223(1):14-26. doi: 10.1002/jcp.22011. J Cell Physiol. 2010. PMID: 20049846 Review. - SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy.
Johnson FM, Gallick GE. Johnson FM, et al. Anticancer Agents Med Chem. 2007 Nov;7(6):651-9. doi: 10.2174/187152007784111278. Anticancer Agents Med Chem. 2007. PMID: 18045060 Review.
Cited by
- Antitumor effects of Dasatinib on laryngeal squamous cell carcinoma in vivo and in vitro.
Song Y, Sun X, Bai WL, Ji WY. Song Y, et al. Eur Arch Otorhinolaryngol. 2013 Mar;270(4):1397-404. doi: 10.1007/s00405-013-2394-3. Epub 2013 Feb 13. Eur Arch Otorhinolaryngol. 2013. PMID: 23404469 Free PMC article. - A novel 3D fibril force assay implicates src in tumor cell force generation in collagen networks.
Polackwich RJ, Koch D, Arevalo R, Miermont AM, Jee KJ, Lazar J, Urbach J, Mueller SC, McAllister RG. Polackwich RJ, et al. PLoS One. 2013;8(3):e58138. doi: 10.1371/journal.pone.0058138. Epub 2013 Mar 11. PLoS One. 2013. PMID: 23536784 Free PMC article. - Cancer-targeted therapies and radiopharmaceuticals.
Rachner TD, Jakob F, Hofbauer LC. Rachner TD, et al. Bonekey Rep. 2015 Jun 3;4:707. doi: 10.1038/bonekey.2015.76. eCollection 2015. Bonekey Rep. 2015. PMID: 26131359 Free PMC article. Review. - Emerging Role and Targeting of Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6) in Human Malignancies.
Johnson B, Mahadevan D. Johnson B, et al. Clin Cancer Drugs. 2015 Feb;2(2):100-111. doi: 10.2174/2212697X02666150602215823. Clin Cancer Drugs. 2015. PMID: 27595061 Free PMC article. - The adaptor protein Tom1L1 is a negative regulator of Src mitogenic signaling induced by growth factors.
Franco M, Furstoss O, Simon V, Benistant C, Hong WJ, Roche S. Franco M, et al. Mol Cell Biol. 2006 Mar;26(5):1932-47. doi: 10.1128/MCB.26.5.1932-1947.2006. Mol Cell Biol. 2006. PMID: 16479011 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous